The U.S. Food and Drug Administration is increasingly relying on expedited approvals of drugs that skip or shorten test trials. This is a departure from past practice, when most drugs for serious illnesses were given greater scrutiny before being allowed to enter the market.
Source: Peter Loftus, “Fast-Track Drug Approval, Designed for Emergencies, Is Now Routine,” The Wall Street Journal, July 5, 2019, https://tinyurl.com/yycoqw8z
Data for the graphic are as follows:
|Year||Percentage of Expedited Approvals|